Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sunrest LifescienceNSE:SUNREST +4.21%42 EV-to-EBITDA is 4.78 as of Aug. 29, 2026, which is 59% below its 10-year median of 11.56. GuruFocus rates NSE:SUNREST with a GF Score™ of 42/100. The stock has 6 warning signs investors should review. Among 517 Healthcare Providers & Services companies, Sunrest Lifescience ranks better than 86.07% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Sunrest Lifescience's enterprise value is ₹443.2 Mil.
Sunrest Lifescience's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was ₹92.6 Mil. Therefore, Sunrest Lifescience's EV-to-EBITDA for today is 4.78.
The historical rank and industry rank for Sunrest Lifescience's EV-to-EBITDA or its related term are showing as below:
NSE:SUNREST'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 3.02 Med: 11.56 Max: 35.36
Current: 4.78
During the past 7 years, the highest EV-to-EBITDA of Sunrest Lifescience was 35.36. The lowest was 3.02. And the median was 11.56.
NSE:SUNREST's EV-to-EBITDA is ranked better than 86.07% of 517
companies
in the Healthcare Providers & Services industry
Industry Median: 10.49
vs NSE:SUNREST: 4.78
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Sunrest Lifescience's PE Ratio (TTM) for today is calculated as:
Sunrest Lifescience's share price for today is ₹39.60.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sunrest Lifescience's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0.736.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Sunrest Lifescience's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, Sunrest Lifescience's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sunrest Lifescience EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Sunrest Lifescience's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Sunrest Lifescience's EV-to-EBITDA falls into.
Sunrest Lifescience's current Enterprise Value is ₹443.2 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sunrest Lifescience's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was ₹92.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sunrest Lifescience (NSE:SUNREST) has a EV-to-EBITDA of 4.78 as of Aug. 29, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Sunrest Lifescience. This is 59% below median its historical median of 11.56. Over the past decade, Sunrest Lifescience's EV-to-EBITDA has ranged from 3.02 to 35.36. According to the industry distribution chart, Sunrest Lifescience ranks #72 out of 517 companies in the Healthcare Providers & Services industry, placing it in the top 13.9%.
Is Sunrest Lifescience's EV-to-EBITDA too high?
Sunrest Lifescience's current EV-to-EBITDA of 4.78 is 59% below median its 10-year median of 11.56. Over the past 10 years, this metric has ranged from a low of 3.02 to a high of 35.36. The Healthcare Providers & Services industry median EV-to-EBITDA is 10.49. Sunrest Lifescience's value of 4.78 is 54.4% below this industry median. Based on the distribution chart, Sunrest Lifescience ranks #72 out of 517 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Sunrest Lifescience has a GF Score™ of 42/100, reflecting its overall financial health beyond just this single metric.
How does Sunrest Lifescience's EV-to-EBITDA compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Sunrest Lifescience ranks #72 out of 517 companies for EV-to-EBITDA. This places Sunrest Lifescience in the top 14% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 10.49. Sunrest Lifescience's value of 4.78 is 54.4% below this benchmark. Historically, Sunrest Lifescience's own EV-to-EBITDA has ranged from 3.02 to 35.36 over the past decade. While the company's 10-year median is 11.56 vs. the industry median of 10.49, Sunrest Lifescience has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 10.49, based on 517 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sunrest Lifescience's current EV-to-EBITDA of 4.78 is 54.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Sunrest Lifescience. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 10.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sunrest Lifescience's current EV-to-EBITDA is 4.78, which is 59% below median its own 10-year median of 11.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sunrest Lifescience stock overvalued right now?
Sunrest Lifescience (NSE:SUNREST) has a current EV-to-EBITDA of 4.78. The current EV-to-EBITDA is 4.78, which is 59% below median its 10-year median of 11.56 and 54.4% below the Healthcare Providers & Services industry median of 10.49. Sunrest Lifescience's overall GF Score™ is 42/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Sunrest Lifescience (NSE:SUNREST), the current EV-to-EBITDA is 4.78 as of Aug. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sunrest Lifescience Ltd is engaged in the trading business of pharmaceutical products, including capsules, tablets, syrups, ointments, gels, mouthwash, and toothpaste on a wholesale and retail basis. Its product portfolio covers categories such as anti-bacterial, anti-diarrheal, anti-fungal, anti-malarial, anti-diabetic, dental care, anti-inflammatory, nutraceuticals, and more. The company works with a network of suppliers and super suppliers, distributing products to chemists, hospitals, and dispensaries across multiple Indian states. Sunrest relies on both in-house manufacturing through its group company Trilend Pharmaceuticals and third-party manufacturers, emphasizing quality control and regulatory compliance.
42GF Score
Get the complete analysis for NSE:SUNREST
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SUNREST has been successfully added to your 
